<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04179136</url>
  </required_header>
  <id_info>
    <org_study_id>CardioFlax study</org_study_id>
    <nct_id>NCT04179136</nct_id>
  </id_info>
  <brief_title>The Role of Gut Microbiome on Cardiovascular Health Benefits of Dietary Lignans (CardioFlax Study).</brief_title>
  <official_title>The Role of Gut Microbiome on Cardiovascular Health Benefits of Dietary Lignans ( CardioFlax Study).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>King's College London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>King's College London</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to investigate the effects of gut microbial metabolism of flaxseed
      lignans on cardiovascular health. Enterolactone is the main gut microbial metabolite of
      lignans. The study population will be stratified in low and high enterolactone producers and
      will investigate whether high producers will have greater benefits than low producers, and
      whether low producers may become high producers after daily consumption of lignans over 8
      weeks. The investigators will evaluate changes in endothelial function, blood pressure,
      arterial stiffness, insulin resistance, lipid profile and gut microbiome composition after 8
      weeks daily consumption of flaxseed lignans.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Epidemiological studies have shown inverse relation between enterolactone levels and
      cardiovascular mortality. Participants will be stratified from first phase (NCT03573414) and
      then randomly allocated to treatment or placebo. Outcomes are measured at baseline and after
      8 weeks post consumption.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 25, 2019</start_date>
  <completion_date type="Anticipated">January 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Double blinded randomized control trial</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in flow-mediated dilation (FMD)</measure>
    <time_frame>Baseline vs 8 weeks post-consumption</time_frame>
    <description>To investigate the effect of daily consumption of 300 mg of flaxseed (SDG) extract vs Placebo for 8 weeks on endothelium-dependent flow mediated dilation (FMD) of the brachial artery (0, 8 weeks)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in flow-mediated dilation (FMD)</measure>
    <time_frame>Day 0, Day1 post-consumption</time_frame>
    <description>To investigate the acute effect of 300 mg of flaxseed (SDG) extract vs Placebo on endothelium-dependent flow mediated dilation (FMD) of the brachial artery after 24- hour post-consumption.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in office blood pressure</measure>
    <time_frame>Day 0, Day 1 and 8 weeks post-consumption</time_frame>
    <description>To investigate the effect of 300 mg flaxseed lignans (SDG) extract vs Placebo on peripheral systolic and diastolic blood pressure, and heart rate after 8 weeks daily consumption.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in pulse wave velocity (PWV)</measure>
    <time_frame>Baseline vs 8 weeks post-consumption</time_frame>
    <description>To determine the effect of 300 mg of lignans (SDG) vs Placebo on pulse wave velocity (PWV ) using a Sphygmocor device, after 8 weeks daily consumption</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in augmentation Index (AIx)</measure>
    <time_frame>Baseline vs 8 weeks post-consumption</time_frame>
    <description>To determine the effect of 300 mg of lignans (SDG) vs Placebo on augmentation index (PWA) using a Sphygmocor device, after 8 weeks daily consumption</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Total cholesterol</measure>
    <time_frame>Baseline vs 8 weeks post-consumption</time_frame>
    <description>To investigate the effect of 300 mg Lignans (SDG) extract vs Placebo on blood lipids Total cholesterol after 8 weeks daily consumption</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in blood inflammatory markers (IL-6)</measure>
    <time_frame>Baseline vs 8 weeks post-consumption</time_frame>
    <description>To investigate the effect of 300 mg lignans (SDG) extract vs Placebo on inflammation markers (IL-6) after 8 weeks daily consumption.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in glucose marker</measure>
    <time_frame>Baseline vs 8 weeks post-consumption</time_frame>
    <description>To investigate the effect of 300 mg lignans (SDG) extract vs Placebo on glucose levels (glucose) after 8 weeks daily consumption.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in blood lipid (HDL cholesterol ) concentrations</measure>
    <time_frame>Baseline vs 8 weeks post-consumption</time_frame>
    <description>o investigate the effect of 300 mg Lignans (SDG) extract vs Placebo on blood lipids (HDL)after 8 weeks daily consumption</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in blood lipid (LDL cholesterol )concentrations</measure>
    <time_frame>Baseline vs 8 weeks post-consumption</time_frame>
    <description>o investigate the effect of 300 mg Lignans (SDG) extract vs Placebo on blood lipids( LDL cholesterol) after 8 weeks daily consumption</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in blood lipid (triglycerides) concentrations</measure>
    <time_frame>Baseline vs 8 weeks post-consumption</time_frame>
    <description>o investigate the effect of 300 mg Lignans (SDG) extract vs Placebo on blood lipids (triglycerides) after 8 weeks daily consumption</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in blood inflammatory markers (CRP)</measure>
    <time_frame>Baseline vs 8 weeks post-consumption</time_frame>
    <description>To investigate the effect of 300 mg lignans (SDG) extract vs Placebo on inflammation markers ( CRP) after 8 weeks daily consumption.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in insulin markers</measure>
    <time_frame>Baseline vs 8 weeks post-consumption</time_frame>
    <description>To investigate the effect of 300 mg lignans (SDG) extract vs Placebo on glucose levels (insulin) after 8 weeks daily consumption.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in glucose (HbA1c) markers</measure>
    <time_frame>Baseline vs 8 weeks post-consumption</time_frame>
    <description>To investigate the effect of 300 mg lignans (SDG) extract vs Placebo on glucose levels (HbA1c) after 8 weeks daily consumption.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in metabolic (poly)phenol metabolite concentrations</measure>
    <time_frame>Baseline, 24 hand 8 weeks post-consumption</time_frame>
    <description>To determine the plasma levels of polyphenol metabolites after acute and chronic consumption of flaxseed lignans (SDG).Measured by liquid chromotography-mass spectrometry (LC/MS)</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in metabolic (poly)phenol metabolite concentrations</measure>
    <time_frame>Baseline vs 8 weeks post-consumption</time_frame>
    <description>To determine the urine levels of polyphenol metabolites baseline and chronic consumption of flaxseed lignans (SDG). Measured by liquid chromotography-mass spectrometry (LC/MS)</description>
  </other_outcome>
  <other_outcome>
    <measure>Gut microbiome composition</measure>
    <time_frame>Baseline vs 8 weeks post-consumption</time_frame>
    <description>To investigate changes in gut microbiota composition and diversity after 8 weeks consumption of flaxseed lignans (SDG) extract.</description>
  </other_outcome>
  <other_outcome>
    <measure>Menopausal symptoms</measure>
    <time_frame>Baseline vs 8 weeks post-consumption</time_frame>
    <description>To investigate the effect of 300 mg flaxseed lignans (SDG) extract vs Placebo on menopausal symptoms using menopausal questionnaire for women over 45 years.</description>
  </other_outcome>
  <other_outcome>
    <measure>Homeostatic model assessment</measure>
    <time_frame>Baseline vs 8 weeks post-consumption</time_frame>
    <description>To assess insulin resistance (IR) using homeostatic model assessment (HOMA).</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">68</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>High enterolactone producer's (intervention)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>lignan capsules contain 300 mg flaxseed (SDG) extract</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High enterolactone producer's (Control)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo treatment matching intervention</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low enterolactone producer's (intervention)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>lignan capsules contain 300 mg flaxseed (SDG) extract</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low enterolactone producer's (Control)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo treatment matching intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>lignan capsules contain 300 mg flaxseed (SDG) extract</intervention_name>
    <description>lignan capsules contain 300 mg flaxseed (SDG) extract</description>
    <arm_group_label>High enterolactone producer's (intervention)</arm_group_label>
    <arm_group_label>Low enterolactone producer's (intervention)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo treatment matching intervention</intervention_name>
    <description>Placebo treatment matching intervention</description>
    <arm_group_label>High enterolactone producer's (Control)</arm_group_label>
    <arm_group_label>Low enterolactone producer's (Control)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy women aged 20-70 years

          -  BMI between 18 and 35 kg/m2

          -  Subjects are willing to maintain their normal eating/drinking habits and exercise
             habits to avoid changes in body weight over the duration of the study

          -  Are able to understand the nature of the study

          -  Able to give signed written informed consent

          -  Signed informed consent form

        Exclusion Criteria:

          -  Medical history of cardiovascular disease including coronary artery disease,
             cerebrovascular disease and peripheral artery disease

          -  Hypertensive, as defined as SBP superior or equal to 140 mmHg, and CBP superior or
             equal to 90 mmHg

          -  Participants with BMI superior to 35 kg/m2, and BMI below 18 kg/m2

          -  Medical history of diabetes mellitus, metabolic syndrome, terminal renal failure or
             malignancies

          -  Abnormal heart rhythm (lower or higher than 60-100 bmp)

          -  Allergies to flaxseed or other significant food allergy

          -  Subjects under medication that can affect the cardiovascular system or on
             vitamin/dietary supplements.

          -  Subjects who have lost more than 10% of their weight in the past 6 months or are
             currently in a diet

          -  Subjects who reported participant in another study within one month before the study
             start

          -  Smoker Subjects

          -  Pregnant women or planning to become pregnant in the next 6 months

          -  Any reason or condition that in the judgment of the clinical investigator(s) may put
             the subject at unacceptable risk or that may preclude the subject from understanding
             or complying with the study's requirements.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr.Ana Rodriguez-Mateos, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>King's College London</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dr.Ana Rodriguez-Mateos, PhD</last_name>
    <phone>+44 (0)20 7848 4349</phone>
    <email>ana.rodriguez-mateos@kcl.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dr.Wendy Hall, PhD</last_name>
    <phone>+44 (0)20 7848 4349</phone>
    <email>Wendy.Hall@kcl.ac.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>King's College London</name>
      <address>
        <city>London</city>
        <zip>SE1 9NH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wafa Alotaibi, MSc</last_name>
      <email>wafa.alotaibi@kcl.ac.uk</email>
    </contact>
    <contact_backup>
      <last_name>Ana Rodriguez-Mateos, Phd</last_name>
      <email>ana.rodriguezmateos@kcl.ac.uk</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 21, 2019</study_first_submitted>
  <study_first_submitted_qc>November 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 27, 2019</study_first_posted>
  <last_update_submitted>December 10, 2019</last_update_submitted>
  <last_update_submitted_qc>December 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cardiovascular system Polyphenols</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

